Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Scribd Logo
Upload

Welcome to Scribd!

  • 3 views

    Pedia Roel

    Uploaded by

    khenliyanah

    Copyright:

    © All Rights Reserved
    Download as DOC, PDF, TXT or read online from Scribd

    Pedia Roel

    Uploaded by

    khenliyanah
    3 views2 pages

    Original Title

    Pedia-roel

    Copyright

    © © All Rights Reserved

    Available Formats

    DOC, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Copyright:

    © All Rights Reserved
    Download as DOC, PDF, TXT or read online from Scribd
    Download as doc, pdf, or txt
    3 views2 pages

    Pedia Roel

    Uploaded by

    khenliyanah

    Copyright:

    © All Rights Reserved
    Download as DOC, PDF, TXT or read online from Scribd
    Download as doc, pdf, or txt
    of 2

    (Kawasaki Disease)

    Abstract

    Kawasaki disease is an acute, self-limited vasculitis of unknown etiology that occurs


    predominantly in infants and children. If not treated early with high-dose intravenous
    immunoglobulin, 1 in 5 children develop coronary artery aneurysms; this risk is reduced 5-fold if
    intravenous immunoglobulin is administered within 10 days of fever onset. Coronary artery
    aneurysms evolve dynamically over time, usually reaching a peak dimension by 6 weeks after
    illness onset. Almost all the morbidity and mortality occur in patients with giant aneurysms. Risk
    of myocardial infarction from coronary artery thrombosis is greatest in the first 2 years after
    illness onset. However, stenosis and occlusion progress over years. Indeed, Kawasaki disease
    is no longer a rare cause of acute coronary syndrome presenting in young adults. Both coronary
    artery bypass surgery and percutaneous intervention have been used to treat Kawasaki disease
    patients who develop myocardial ischemia as a consequence of coronary artery aneurysms and
    stenosis.

    Critical Analysis

    Diagnosing Kawasaki Disease can be challenging due to its variable presentation and lack of
    specific laboratory tests. Early recognition of clinical features such as prolonged fever,
    mucocutaneous manifestations, lymphadenopathy, and systemic inflammation is crucial to
    initiate timely treatment and prevent coronary artery abnormalities. Intravenous immunoglobulin
    (IVIG) and aspirin therapy have been shown to reduce the risk of coronary artery aneurysms
    when administered promptly during the acute phase of the illness. However, a subset of patients
    may be refractory to initial treatment, highlighting the need for alternative therapies and ongoing
    research to improve outcomes. Long-term cardiac monitoring is essential to detect and manage
    late cardiovascular complications, including coronary artery stenosis and myocardial infarction.

    Recommendation

    In managing Kawasaki disease cases, prompt recognition and treatment are essential.
    Healthcare providers should maintain a high index of suspicion for Kawasaki Disease in children
    presenting with prolonged fever and characteristic clinical features. Early initiation of intravenous
    immunoglobulin (IVIG) therapy, typically within the first ten days of illness onset, along with
    aspirin therapy, has been shown to reduce the risk of coronary artery complications.
    Multidisciplinary collaboration among pediatricians, cardiologists, rheumatologists, and infectious
    disease specialists is essential to ensure comprehensive care and optimize patient outcomes.
    Long-term follow-up with regular cardiac assessments, including echocardiography, is crucial for
    monitoring coronary artery abnormalities and other cardiovascular anomalies. Education of
    caregivers about the signs and symptoms of Kawasaki Disease and the importance of
    adherence to treatment and follow-up protocols is also essential. By implementing these
    recommendations, healthcare providers can effectively manage KD cases and reduce the risk of
    long-term cardiovascular complications.
    Reference (APA format)

    Gerding, R. (2011). Kawasaki Disease: A review. Journal of Pediatric Health Care, 25(6), 379–
    387.

    https://doi.org/10.1016/j.pedhc.2011.07.007

    Dionne, A., Melish, M. E., Newburger, J. W., & Dahdah, N. (2019). The treatment of Kawasaki
    syndrome with corticosteroids. The Journal of Pediatrics, 209, 38-44. Gordon, J. B., Kahn, A. M.,
    Burns, J. C., & Institute of Medicine (US) Committee on the Prevention of Destructive Kawasaki
    Disease (2020)

    (Signature)
    Submitted by: Roel Villanueva
    Year & Section

    (Signature)
    Submitted to: Mrs.Ria Bisaya
    Clinical Instructor

    You might also like